Orogen Therapeutics Advances Multiple Programs Toward IND-Enabling Studies
WOBURN, MA, March 28, 2025 – Orogen Therapeutics announced today that multiple therapeutic programs from its immuno-inflammatory pipeline have advanced toward IND-enabling studies, marking significant progress in the company's mission to develop novel oral small molecule therapeutics.
The advancement is based on compelling preclinical data demonstrating both efficacy and safety profiles for Orogen's lead compounds targeting validated cytokine pathways in immuno-inflammatory disorders.
Pipeline Progress
"Advancing multiple programs simultaneously toward clinical development demonstrates the power and efficiency of our integrated discovery platform," said Mark Pykett, CEO of Orogen Therapeutics. "We're particularly excited about the potential for these oral small molecule alternatives to current biological therapies."
Related Articles
Orogen Therapeutics and Chemspace/Enamine Announce a Strategic Collaboration to Enable Unique REAL-Driven DNA Encoded Small Molecule Libraries
Strategic partnership combines Chemspace's ultra-large chemical datasets and Enamine's REAL design principles with Orogen's AI-enabled DEL technology to advance next-generation drug discovery.
Orogen Therapeutics Announces Expansion of Scientific Advisory Board with Drug Discovery and Development Experts
Industry leaders Humphrey Gardner and Christopher Winter, PhD join Orogen's expanded SAB as the Company advances its AI-enabled DNA-encoded library platform.
"Orogen is elevating new heights in drug discovery, integrating massive chemical libraries, target-specific screening, and AI-based computation to propel the generation of novel medicines."
Mark Pykett
CEO, Orogen Therapeutics